To ensure access to quality and affordable care for cancer patients within their communities.



Clinical Pathways

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Email Newsletter
Upcoming Events

LunchTime Series Webinar
Wednesday, August 27, 2014 from 12:00pm - 1:30pm PST Topic: ""Eliminating Collection Costs While Reducing Accounts Receivables by More Than 61%"
Presented by:
Shawn Ecksel
Vice President, Sales and Development
For more information and to register, email
or call 909-985-9061 ext. 1.

LunchTime Series Teleconference

Wednesday, August 27th at 12:00PM-PST
Wednesday, September 24th at 12:00PM-PST

To RSVP please email Danielle Overman at

Save-the-date! Friday, September 19, 2014!
MOASC Nurse Program in Pasadena.
7:30am - 8:00am Registration – Breakfast – Exhibit Hall
8:00am   Welcome & Introductions
8:15am  - 9:15am Oral Adherence presented by:
Flora Woo, MSN, RN, Senior Clinical Nurse Consultant, Celgene Corporation
9:15am – 9:30am Break/Refreshments – Exhibit Hall
9:35am – 10:55am Compassion Fatigue: Building Resilience in Oncology Nurses presented by:
 Katherine Joyce Janzen RN, MN, ONC(C)
Assistant Professor, School of Nursing and Midwifery
Faculty of Health and Community Studies
Mount Royal University, Calgary, Alberta, Canada.
11:00am – 12:00pm  The Art of Active Listening (AAL) presented by:
Ms. Selinza Ann Mitchell, CNS, Oncology Clinical Nurse Educator, Pfizer Oncology
For more information and to register, email
or call 909-985-9061 ext. 1.

Save-the-date!  Friday, November 14, 2014!
The MOASC Advisory Summit will be held at the
InterContinental Hotel in Century City.
The schedule is:
12:00pm - 5:00pm   B-Cell Advisory Board Meeting 
 (limited to 10 physicians)
3:00pm - 5:00pm     Pathways Advisory Board Meeting  (limited to 15 physicians)
3:00pm - 5:00pm  myPlan Lung Cancer Prognostic Test Advisory    (limited to 20 physicians)
5:00pm - 6:00pm     Reception - Exhibit Hall
6:30pm - 8:15pm     Dinner Program
For more information and to register, email
or call 909-985-9061 ext. 1.This meeting precedes Research To Practice - Year In Review Program with Dr. Neil Love on
Saturday, November 15, 2014.
For more information visit:

Hot Topics

California's Department of Managed Health Care (DMHC) has issued fines at more than twice the rate of recent years against health plans that did not pay providers in a timely manner. California health plans have long been required to pay providers in a timely manner (i.e., within 45 days of receiving a claim). Click here for more information.

Noridian/JEMAC's website ( has posted the following updates: Draft LCDs Published for Review and Comments (including ESAs and MolDx), September Web-based Workshops, and PET Scans Coverage-R4. Click here for more information.

Medi-Cal is experiencing technical difficulties: 1) Accepting claim attachments; 2) with the 835 files created on August 6, 13 and 20, and; 3) verifying the status of volsers. As a result, providers and submitters are unable to obtain a volser status through Transaction Services. Systems personnel are aware of these problems and are working on a resolution. Medi-Cal apologizes for the inconvenience. Please go to for future updates. Click here for more information.

CMS, in an e-mail to COA President Bruce Gould, M.D., amongst others, says it has developed a provisional design of a new oncology payment model. While the model is not final, CMS wanted to share the provisional design elements with interested stakeholders. If CMS decides to move forward with an oncology model, the CMS Innovation Center will publish the final model with additional detail regarding participation in the model, and will post a Request for Applications on the Innovation Center website. In the meantime, view the provisional model at
. Click here for more information.

MOASC Information
If you did not attend last Wednesday's LunchTime Series Teleconference, "California Regulated Medical Waste Management and Proper Waste Segregation," presented by Richard Best, Technical Director, Stericycle, Inc., you can listen to the recording by dialing 1-888-203-1112 and enter the pass code 353441415#This recording will be available for the next 30 days. To view the handouts for the presentation, please email Danielle Overman at

Novartis is pleased to confirm that ZYKADIA™ (ceritinib) capsules has been approved by the US Food and Drug Administration (FDA) on April 29, 2014 and is available in a 150 mg strength. Novartis Pharmaceuticals Corporation will sell ZYKADIA (ceritinib) capsules to McKesson Specialty Care Distribution Corporation for its sale in the United States to certain specialty pharmacies and most other pharmacies excluding retail pharmacies.

  • ZYKADIA is a once-daily, oral anaplastic lymphoma kinase (ALK) inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or who are intolerant to crizotinib. This indication is approved under accelerated approval, based on tumor response rate and duration of response.  An improvement in survival or disease-related symptoms has not been established.  Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Please see accompanying full Prescribing Information or visit

MOASC held its Spring General Membership Meeting on May 22nd at the Queen Mary in Long Beach. In case you missed it, below is a synopsis of the evening:

Oncology Leadership Economic Conference - Roundtable discussion with the MOASC Board of Directors and Industry Partners.
Exhibitions & Networking Reception.  This meeting was sponsored in part by: BMS, Merck Oncology, Myriad, Oncology Supply and Pfizer.
Robert Moss, M.D., MOASC President welcomed all attendees and began with introductions.
Peter Yu, M.D., Director of Cancer Research, Palo Alto Medical Foundation, President, ASCO presented: "ASCO Initiatives".
Jennifer Malin, M.D., Medical Director of Oncology and Care Management, WellPoint and Sylvia Carlisle, M.D., Medical Director for Anthem presented: "California Changing Healthcare Landscape: Implications for Cancer Care".
Kathy Fairbanks, Patients and Providers to Protect Access and Contain Health Costs, the campaign to defeat the MICRA ballot measure.


Thank you to the following sponsors for assisting MOASC in achieving their mission.

Bayer Healthcare Pharmaceuticals, Cardinal Health Specialty Solutions, Lilly Oncology, Oncology Supply, Teva Oncology

Amgen, Astellas Oncology, Novartis
AMAG Pharmaceuticals, AstraZeneca, Dendreon, Genentech, Genomic Health, McKesson Specialty Health, Merck Oncology, Millennium, Onyx Pharmaceuticals, Pfizer, Pharmacyclics, Rosetta Genetics, Seattle Genetics, Sanofi Oncology

BMS, Myriad

© 2008 - 2014 Medical Oncology Association of Southern California
P.O. Box 161   •    Upland, CA 91785
Phone: (909) 985-9061   •    Fax: (909) 985-8581   •   email:

Open Central 

inland empire website design wow webs